Your browser doesn't support javascript.
loading
Partial Response to Antidepressant Treatment: The Role of Nutraceutical Compounds.
Girone, Nicolaja; Benatti, Beatrice; Molteni, Laura; Cassina, Niccolò; Giacovelli, Luca; Arici, Chiara; Dell'Osso, Bernardo.
Afiliação
  • Girone N; Luigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy.
  • Benatti B; Luigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy.
  • Molteni L; "Aldo Ravelli" Center for Nanotechnology and Neurostimulation, University of Milan, Milan, Italy.
  • Cassina N; Luigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy.
  • Giacovelli L; Southern Health National Health Service Foundation Trust, Southampton, UK" and "University Department of Psychiatry, Academic Centre, Southampton, UK.
  • Arici C; Luigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy.
  • Dell'Osso B; Luigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy.
Clin Neuropsychiatry ; 20(3): 183-192, 2023 Jun.
Article em En | MEDLINE | ID: mdl-37522109
ABSTRACT

Objective:

Depression represents one of the most severe psychiatric disorders, characterized by low mood episodes, as well as loss of interest. Major Depressive Episodes (MDE) treatment relies primarily on monoaminergic prescriptions. However, although the presence of many antidepressant medications, their efficacy is still partial. A promising intervention to improve antidepressant treatment may be the use of adjunctive nutraceuticals. Aim of the present study was to assess the efficacy of a N-Acetyl-cysteine, S-Adenosyl-L-Methionine and Folic acid's combination for the treatment of depressive symptoms in a sample of MDE patients.

Method:

Fifty outpatients with a MDE diagnosis in the context of different psychiatric disorders such as Major Depression, Bipolar Disorder, Anxiety disorders, and Personality disorders were recruited. The sample was divided into different groups based on the nutraceutical administration a) concurrently with an AD (starter group); b) add-on to an already prescribed treatment; c) single treatment.

Results:

A significant reduction of CGI-Severity and Improvement scores from baseline to the end of treatment was found. Moreover, the starter group showed a significantly greater CGI-Improvement score compared to the other groups. Ninety-four percent of patients did not show any side effects.

Conclusions:

The present study showed promising results for the use of nutraceuticals in the add-on treatment of MDE. Those compounds may be considered a versatile, tolerable, and effective add-on treatment for the reduction of depressive symptoms impact and for improving the functioning of patients affected by MDE.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Neuropsychiatry Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Neuropsychiatry Ano de publicação: 2023 Tipo de documento: Article